Lack of strong effect modification by NFE2L2/CYP3A5/ABO of the risk of venous thrombosis associated with oral hormone therapy

J Thromb Haemost. 2013 Aug;11(8):1617-9. doi: 10.1111/jth.12309.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • ABO Blood-Group System / metabolism*
  • Administration, Oral
  • Aged
  • Alleles
  • Case-Control Studies
  • Cytochrome P-450 CYP3A / metabolism*
  • Female
  • Gene Frequency
  • Genetic Variation
  • Hormones / administration & dosage
  • Humans
  • Middle Aged
  • NF-E2-Related Factor 2 / metabolism*
  • Polymorphism, Single Nucleotide
  • Postmenopause
  • Pulmonary Embolism / blood
  • Regression Analysis
  • Risk Factors
  • Venous Thrombosis / blood
  • Washington

Substances

  • ABO Blood-Group System
  • Hormones
  • NF-E2-Related Factor 2
  • NFE2L2 protein, human
  • CYP3A5 protein, human
  • Cytochrome P-450 CYP3A